肌肉质量与老年房颤患者直接口服抗凝药活性
本研究为前瞻性队列研究,纳入62例65岁以上房颤患者,服用利伐沙班或阿哌沙班。采用生物电阻抗和双能X线吸收法测量四肢瘦体重,标准化抗Xa法测峰谷DOAC水平。多变量模型显示较低ALM与谷值和峰值超治疗水平独立相关,ALM加入年龄、体重、肾功能模型可改善判别。
要点
- 低四肢瘦体重与老年房颤患者DOAC谷值和峰值超治疗水平独立相关
- 16%患者谷值、25%患者峰值DOAC水平超治疗范围
- ALM加入年龄、体重和肾功能模型可改善超治疗DOAC水平的判别
核心结论
- 概念验证研究显示四肢瘦体重与老年房颤患者DOAC水平存在关联,需进一步研究其对出血并发症的影响及ALM指导剂量调整的潜在作用。
研究设计与样本
- 前瞻性队列研究,纳入62例65岁及以上服用利伐沙班或阿哌沙班治疗的房颤患者。
- 用生物电阻抗设备和双能X线吸收扫描仪测量四肢瘦体重,标准化抗Xa法测服药后4小时(峰值)和1小时前(谷值)DOAC水平。
主要发现
- 总体16%患者谷值DOAC水平超治疗范围,25%患者峰值DOAC水平超治疗范围。
- 多变量logistic回归模型中,较低ALM与谷值超治疗DOAC水平独立相关(每降低1 kg OR 1.23,95%CI 1.02–1.49)。
- 较低ALM与峰值超治疗DOAC水平独立相关(每降低1 kg OR 1.18,95%CI 1.02–1.37)。
- ALM加入年龄、总体重和肾功能模型后,对超治疗DOAC水平的判别能力改善。
临床怎么用
- 对老年房颤患者,尤其低肌肉质量者,处方DOAC时应关注超治疗水平及出血风险。
- ALM测量可能有助于识别DOAC超治疗水平风险较高的老年房颤患者。
局限性
- 研究为概念验证性,样本量62例,需进一步研究确定ALM对出血并发症的影响及ALM指导剂量调整的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Direct oral anticoagulants (DOAC) are hydrophilic drugs with plasma levels inversely proportional to lean body mass. Sarcopenic patients with low muscle mass may be at risk for supra-therapeutic DOAC levels and bleeding complications. We therefore sought to examine the influence of lean body mass on DOAC levels in older adults with atrial fibrillation (AF). METHODS: A prospective cohort study was conducted with patients 65 years of age or more receiving rivaroxaban or apixaban for AF. Appendicular lean mass (ALM) was measured using a bioimpedance device and a dual X-ray absorptiometry scanner. DOAC levels were measured using a standardized anti-Xa assay 4 hours after (peak) and 1 hour before (trough) ingestion. RESULTS: The cohort consisted of 62 patients (47% female, 77.0 ± 6.1 years). The prescribed DOACs were apixaban 2.5 mg (21%), apixaban 5 mg (53%), and rivaroxaban 20 mg (26%). Overall, 16% had supra-therapeutic DOAC levels at trough and 25% at peak. In the multivariable logistic regression model, lower ALM was independently associated with supra-therapeutic DOAC levels at trough (odds ratio per ↓ 1-kg 1.23, 95% confidence interval 1.02 to 1.49) and peak (odds ratio per ↓ 1-kg 1.18, 95% confidence interval 1.02 to 1.37). Addition of ALM to a model consisting of age, total body weight, and renal function resulted in improved discrimination for supra-therapeutic DOAC levels. CONCLUSION: Our proof-of-concept study has identified an association between ALM and DOAC levels in older adults with AF. Further research is needed to determine the impact of ALM on bleeding complications and the potential role of ALM-guided dosing for sarcopenic patients.
引用
- Bendayan M, Mardigyan V, Williamson D, et al. Muscle Mass and Direct Oral Anticoagulant Activity in Older Adults With Atrial Fibrillation. J Am Geriatr Soc. 2021. PMID: 33432589. doi:10.1111/jgs.16992
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。